Explore our Microsites

Partner & Employee Best Access
First time users must log in to Best Access via the Virtual Environment, not via this link.

Blog

Jan 12, 2015

Inching Closer to the First Biosimilar Approval in the U.S.

Last week we saw some significant biosimilar activity in the U.S. Specifically, on January 7, 2015, a U.S. Food and Drug Administration (FDA) Advisory Committee (Advisory Committee) voted 14-0 to approve Sandoz Inc.'s (Sandoz) filgrastim biosimilar (referred to as "EP2006") for all five indications of Neupogen® (the reference product manufactured by Amgen Inc. (Amgen)). Specifically, […]
back to top